Neuramis Volume Lidocaine
Non-animal Stabilized Hyaluronic Acid Dermal Filler with SHAPE™ Technology | BDDE ≤0.4ppm | 98.7% Monophasic Gel Homogeneity
Advanced SHAPEâ„¢ Crosslinking Technology
Manufactured under ISO 13485 standards using medical-grade bacterial fermentation HA (20mg/ml). The dual crosslinking process achieves optimal gel elasticity (G’ 240Pa) with 82% persistence at 6 months. Particle size distribution of 95% 320-450μm ensures natural tissue integration. Contains 0.3% lidocaine HCl for procedural comfort, with endotoxin levels <0.05EU/ml validated by LAL testing.
Clinical Advantages
Natural Viscoelasticity
G’ 240Pa | Tan δ 0.23 for natural tissue movement and 12-month persistence in 83% patients
Enhanced Safety Profile
0.4ppm BDDE residue | 99.2% purity level with <0.1% residual proteins
Optimized Comfort
pH 7.2 ±0.3 | 0.3% lidocaine reduces VAS pain scores by 68% versus standard HA
Precision Delivery
27G needle with 40N glide force allows 92% accuracy in deep dermal placement
Product Specifications
- Composition: HA 20mg/ml, Lidocaine HCl 3mg/ml
- Volume: 1.0ml sterile prefilled syringe
- Needle: 27G×1/2″ (0.4×13mm)
- pH: 7.2 ±0.3
- Osmolarity: 290-330 mOsm/kg
- Storage: 2-25°C in original package
Clinical Protocol
- Indications: Mid-deep dermal implantation
- Injection Depth: Subdermal supraperiosteal layer
- Technique: Linear threading or fan distribution
- Max Volume/Site: 0.8ml for cheek augmentation
- Anesthesia: Not required (integrated lidocaine)
- Sterility: Single use only
Aesthetic Applications
Midface Augmentation
Cheek volume restoration: 0.5-0.8ml per side deposited in supraperiosteal plane. 89% patient satisfaction at 6 months in clinical trials.
Nasolabial Folds
0.2-0.4ml per fold using serial puncture technique. Maintains 76% volume correction at 9 months post-treatment.
Marionette Lines
0.3-0.5ml per side with 27G needle. Post-treatment edema resolves within 48hrs in 93% cases.
Clinical Advisory Notice
Notice: Individual results may vary based on tissue characteristics and injection technique. This medical device must be administered by licensed practitioners only. Absolute contraindications include: active skin infections, bleeding disorders, and known hypersensitivity to lidocaine.
Post-procedure monitoring for vascular complications is mandatory. Avoid MRI within 4 weeks post-treatment. Report any persistent erythema or nodules immediately. Not intended for breast augmentation or bone replacement.
